Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design

Michelle S. Miller, Sweta Maheshwari, Fiona M. McRobb, Kenneth W Kinzler, Mario L Amzel, Bert Vogelstein, Sandra B Gabelli

Research output: Contribution to journalArticle

Abstract

PIK3CA, the gene that encodes the catalytic subunit of phosphatidylinositol 3-kinase α (PI3Kα), is frequently mutated in breast and other types of cancer. A specific inhibitor that targets the mutant forms of PI3Kα could maximize treatment efficiency while minimizing side-effects. Herein we describe the identification of novel binding pockets that may provide an opportunity for the design of mutant selective inhibitors. Using a fragment-based approach, we screened a library of 352 fragments (MW < 300 Da) for binding to PI3Kα by X-ray crystallography. Five novel binding pockets were identified, each providing potential opportunities for inhibitor design. Of particular interest was a binding pocket near Glu542, which is located in one of the two most frequently mutated domains.

Original languageEnglish (US)
Pages (from-to)1481-1486
Number of pages6
JournalBioorganic and Medicinal Chemistry
Volume25
Issue number4
DOIs
StatePublished - Feb 15 2017

Fingerprint

Phosphatidylinositol 3-Kinase
Allosteric Site
Binding Sites
X ray crystallography
X Ray Crystallography
Libraries
Catalytic Domain
Genes
Breast Neoplasms

Keywords

  • Fragment-based drug discovery
  • PI3K
  • PIK3CA
  • PIP
  • PIP

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design. / Miller, Michelle S.; Maheshwari, Sweta; McRobb, Fiona M.; Kinzler, Kenneth W; Amzel, Mario L; Vogelstein, Bert; Gabelli, Sandra B.

In: Bioorganic and Medicinal Chemistry, Vol. 25, No. 4, 15.02.2017, p. 1481-1486.

Research output: Contribution to journalArticle

@article{7a240ca3777246ecaf1906b06f421b71,
title = "Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design",
abstract = "PIK3CA, the gene that encodes the catalytic subunit of phosphatidylinositol 3-kinase α (PI3Kα), is frequently mutated in breast and other types of cancer. A specific inhibitor that targets the mutant forms of PI3Kα could maximize treatment efficiency while minimizing side-effects. Herein we describe the identification of novel binding pockets that may provide an opportunity for the design of mutant selective inhibitors. Using a fragment-based approach, we screened a library of 352 fragments (MW < 300 Da) for binding to PI3Kα by X-ray crystallography. Five novel binding pockets were identified, each providing potential opportunities for inhibitor design. Of particular interest was a binding pocket near Glu542, which is located in one of the two most frequently mutated domains.",
keywords = "Fragment-based drug discovery, PI3K, PIK3CA, PIP, PIP",
author = "Miller, {Michelle S.} and Sweta Maheshwari and McRobb, {Fiona M.} and Kinzler, {Kenneth W} and Amzel, {Mario L} and Bert Vogelstein and Gabelli, {Sandra B}",
year = "2017",
month = "2",
day = "15",
doi = "10.1016/j.bmc.2017.01.012",
language = "English (US)",
volume = "25",
pages = "1481--1486",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design

AU - Miller, Michelle S.

AU - Maheshwari, Sweta

AU - McRobb, Fiona M.

AU - Kinzler, Kenneth W

AU - Amzel, Mario L

AU - Vogelstein, Bert

AU - Gabelli, Sandra B

PY - 2017/2/15

Y1 - 2017/2/15

N2 - PIK3CA, the gene that encodes the catalytic subunit of phosphatidylinositol 3-kinase α (PI3Kα), is frequently mutated in breast and other types of cancer. A specific inhibitor that targets the mutant forms of PI3Kα could maximize treatment efficiency while minimizing side-effects. Herein we describe the identification of novel binding pockets that may provide an opportunity for the design of mutant selective inhibitors. Using a fragment-based approach, we screened a library of 352 fragments (MW < 300 Da) for binding to PI3Kα by X-ray crystallography. Five novel binding pockets were identified, each providing potential opportunities for inhibitor design. Of particular interest was a binding pocket near Glu542, which is located in one of the two most frequently mutated domains.

AB - PIK3CA, the gene that encodes the catalytic subunit of phosphatidylinositol 3-kinase α (PI3Kα), is frequently mutated in breast and other types of cancer. A specific inhibitor that targets the mutant forms of PI3Kα could maximize treatment efficiency while minimizing side-effects. Herein we describe the identification of novel binding pockets that may provide an opportunity for the design of mutant selective inhibitors. Using a fragment-based approach, we screened a library of 352 fragments (MW < 300 Da) for binding to PI3Kα by X-ray crystallography. Five novel binding pockets were identified, each providing potential opportunities for inhibitor design. Of particular interest was a binding pocket near Glu542, which is located in one of the two most frequently mutated domains.

KW - Fragment-based drug discovery

KW - PI3K

KW - PIK3CA

KW - PIP

KW - PIP

UR - http://www.scopus.com/inward/record.url?scp=85010443302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010443302&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2017.01.012

DO - 10.1016/j.bmc.2017.01.012

M3 - Article

VL - 25

SP - 1481

EP - 1486

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 4

ER -